CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
NB-001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05290493
NCT05290493Phase 2Completed
CompareCT.gov

A Randomized, Placebo-Controlled Crossover Trial to Assess the Safety and Efficacy of NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

Nobias Therapeutics, Inc.·interventional·Posted Mar 22, 2022·Updated Feb 10, 2025

In Brief

A Phase 2 clinical trial evaluating NB-001 and Placebo for 22q11 Deletion Syndrome. Completed, enrolled 37 participants across 4 sites in 2 countries.

Detailed Summary

This is a Phase 2, randomized, placebo-controlled crossover trial to assess the safety and efficacy of NB-001 in children and adolescents with 22q11DS that manifest commonly associated neuropsychiatric symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Conditions22q11 Deletion Syndrome
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedMar 22, 2022
Enrollment StartFeb 10, 2022
Primary CompletionJun 1, 2023
Study CompletionJun 9, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.3 years ago

Interventions

NB-001drug

Non-stimulant modulator of metabotropic glutamate receptors (mGluRs)

Placeboother

Matching, inactive placebo